10 July 2018 Sophie Cairns
Takeda’s proposed purchase of Shire has led to shareholder dissent; however, M&A is expected to continu
Customer Logins
Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.
Customer Logins
Life Sciences Research and Analysis
Stay ahead of the curve with human – not artificial – intelligence.
Industry insights from the IHS Markit Life Sciences team covering market access, pricing and reimbursement, emerging markets, generics strategies, therapeutic development pathways, forecasting and market sizing, and general competitive intelligence.
Featured
Browse Content
-
-
22 May 2018 Gustav Ando
Insights from ISPOR Baltimore 2018 - digital health
-
18 May 2018 Gustav Ando
Meet us at ISPOR, come see our posters, chat with us about our new product innovations
-
18 May 2018 Milena Izmirlieva
The speech addressed many different elements that create high drug prices in the United States
-
17 May 2018 Brendan Melck
Will shortages lead to changes in the discount-contract system?
-
11 May 2018 Wayne Su
Passing through a portion of rebates could generate substantial savings across the entire Medicare program
-
19 April 2018 Sophie Cairns
Proposed tariffs on Chinese-made goods, including pharmaceutical ingredients, are expected to affect mainly US generics makers.
-
27 March 2018 Ritashree Chakrabarti Tim Dall
Updates to the previous estimates on the burden of disease
-
26 March 2018 Tania Rodrigues
Colombia embraces value-based pricing with Decree 433 of 2018 for new innovative drugs at market entry
-
14 March 2018 Ewa Oliveira da Silva
Is risk-sharing the way forward for this cash-strapped public healthcare system?
-
28 February 2018 Eoin Ryan
Reforms face a difficult path to implementation and the real possibility that they may require careful modification.
-
07 December 2017 Wayne Su
Over the next 10 years, Medicare is expected to save $19 billion
-
04 December 2017 Milena Izmirlieva
Consumer access to effective and affordable medicines in the US is currently inadequately served by the pharmaceutical sector
-
28 November 2017 Eoin Ryan
Luring the EMA to Amsterdam marks a stunning diplomatic coup
-
14 November 2017 Ewa Oliveira da Silva
After October election strengthens government will public healthcare reform see a change?
-
13 November 2017 Anne-Charlotte Ackermann
A value-based approach or a cost-effectiveness or efficacy approach?
-
09 November 2017 Frank Chen
State-by-state projected annual savings to Medicaid from better management of diabetes
-
03 November 2017 Janet Beal
The UK government has issued its much-anticipated response to the Accelerated Access Review (AAR)
-
01 November 2017 Gustav Ando
Meet with our experts and analysts in Glasgow next week
-
23 October 2017 Sophie Cairns
China removes the requirement for local clinical data as part of the drug approval process
-
18 October 2017 Janet Beal
UK access to medicines during and after Brexit
-
16 October 2017 Mohamed Elsayed
A close look at pharma strategy in the Middle East
-
28 September 2017 Tania Rodrigues
A look at how the formal use of IRP is evolving in Brazil compared to Colombia.
-
12 September 2017 Brendan Melck
How does Lithuania plan to reducethe cost of medicines?
-
29 August 2017 Ewa Oliveira da Silva
Where will the EMA locate after Brexit? Can Spain be the answer?
-
17 August 2017 Cameron Lockwood
Is IRP a self sustaining dynamo or soon to be eclipsed?
-
04 August 2017 Sophie Cairns
China adds another 36 medicines to NRDL
-
28 July 2017 Milena Izmirlieva
What was the "Skinny Bill" and what's next?
-
18 July 2017 Cameron Lockwood
At what point will payers decide that opacity in the prices being referenced renders the tool meaningless?
-
11 July 2017 Mohamed Elsayed
Drug shortages and the insufficient control systems in many Middle East countries have also allowed illegal mega-manufacturing factories to work...
-
16 June 2017 Praful Mehta
IHS Markit and Context Matters have for the first time combined these two diverse datasets under one platform so that companies can draw meaningful...
-
08 June 2017 Sophie Cairns
There is increasing public debate over whether Hong Kong's cash-rich government should give more public funding to rare rare-disease medicines....
-
31 May 2017 Milena Izmirlieva
How oil prices undermine a country's ability to pay for medicines
-
24 May 2017 Margaret Labban
A deeper look at US healthcare reform
-
23 May 2017 Gustav Ando
Insights from Day one at ISPOR Boston: US healthcare reform
-
22 May 2017 Gustav Ando
IHS Markit's life sciences team is at ISPOR this week.
-
10 May 2017 Janet Beal
Ukraine has remained the only European country where until very recently patients have largely had to pay out-of-pocket
-
03 May 2017 Brendan Melck
Tensions between the pharmaceutical industry and the social security institutions in Austria are high again
-
13 April 2017 Eoin Ryan
The latest analysis could facilitate future cross-border procurement structures between two or more Nordic countries
-
27 March 2017 Tania Rodrigues
best IRP practice considerations from an industry standpoint
-
21 March 2017 Milena Izmirlieva
A look at some of the developments in cross-country procurement and its possible negative impact for Industry
-
17 March 2017 Praful Mehta
There are clear signals in the EU that the market access environment will become more stringent in the coming years
-
10 March 2017 Cameron Lockwood
A look at SB-17 and what it means for drug pricing in CA
-
06 March 2017 Margaret Labban
The five key principles that need to be present in new legislation that would replace the ACA
-
24 January 2017 Gustav Ando
The Patient Reported Indicators Survey (PaRIS) was formally launched with the ambition of becoming the pre-eminent standard to measure quality...
-
05 January 2017 Tania Rodrigues
A survey of heads of HTA agencies in middle-income countries in Central and Eastern Europe (CEE), Latin America and Asia showed reservations...
-
28 December 2016 Tania Rodrigues
Whilst at ISPOR Vienna, I attended a lively session on national health economic guidelines in Southern Europe that highlighted how current practice...
-
18 November 2016 Janet Beal
A deeper look at the UK's Accelerated Access Review
-
14 November 2016 Cameron Lockwood
An independent assessment of what the pharmaceutical industry is doing to help make medicines more accessible in low- and middle-income countries...
-
11 November 2016 Milena Izmirlieva
Early expectations for the pharmaceutical industry as a result of the Trump election.
-
08 November 2016 Gustav Ando
Proposition 61 on today's California ballot
-
01 November 2016 Gustav Ando
Insights from 19th annual European Congress of ISPORin Vienna
-
28 October 2016 Tania Rodrigues
President Mauricio Macri's bill for the creation of a formal HTA agency
-
26 October 2016 Tania Rodrigues
Education on rising drug costs
-
14 September 2016 Sophie Cairns
Japan's Ministry of Foreign Affairs issued an unusually direct warning of "great turmoil" in a post-Brexit scenario
-
09 September 2016 Eoin Ryan
Ireland's IRP framework underwent a major shake-up in August including an expansion of the basket
-
06 September 2016 Brendan Melck
industry fears hit from reimbursement restrictions
-
02 September 2016 IHS Markit Life Sciences Expert
The new insurance scheme may have negative effects for critically ill-patient groups.
-
19 August 2016 Angelica Kershaw
Public health experts have welcomed the new approach of some pharmaceutical companies towards unveiling new patent policies facilitating access...
-
15 August 2016 Cameron Lockwood
The field of advanced molecular diagnostics, including next-generation sequencing (NGS), has had a complicated history in Germany. When we performed...
-
01 August 2016 Sophie Cairns
A win that is bittersweet
-
28 July 2016 IHS Markit Life Sciences Expert
The people of Syria are now facing the spread of the serious but non-lethal skin infection
-
19 July 2016 Milena Izmirlieva
Pinpointing the exact impact of Brexit on healthcare spending and pharmaceutical spending remains a moving target
-
18 July 2016 Tania Rodrigues
The Spanish health sector is awaiting the formation of a coalition government that will help navigate a complex multi-party regional political...
-
11 July 2016 Eoin Ryan
Major economic and political uncertainty across both UK and EU markets is likely to hamper the EMAs relocation and complicate the decision
-
08 July 2016 Zhang, Jing
What is the economic health of South America for pharma?
-
06 July 2016 Cecilia Chui
Immunotherapy and precision medicine centre-stage at ASCO
-
30 June 2016 Cameron Lockwood
Question marks over the sustainability of industry pipelines have been replaced by question marks over the sustainability of healthcare systems...
-
27 June 2016 Angelica Kershaw
Resolution 2475/2016 authorises the Inter-ministerial Medicines and Medical Devices Pricing Commission (CNPMD) to reduce Glivec's price.
-
A vote to leave the European Union and what it would mean for Britain's place in the world of pharma
20 June 2016 Milena Izmirlieva
As the date for Great Britain's referendum on whether to leave the European Union approaches, the pre-referendum debates have only marginally...
-
17 June 2016 Anne-Charlotte Ackermann
A close look at France's formal BIA and access to HCV meds
-
14 June 2016 Janet Beal
A cheaper, faster track to approve funding for me-too medicines in the UK?
-
10 June 2016 Brendan Melck
A familiar problem in Greece today: trying to implement reforms which are difficult enough to implement in normal circumstances...
-
01 June 2016 Sophie Cairns
Pricing and cost-effectiveness and public hospital discussions from our trip to Asia
-
26 May 2016 Cameron Lockwood
A look at some of the challenges facing the NHS commissioning framework for molecular diagnostic testing
-
23 May 2016 Cameron Lockwood
AA closer look at the access-to-medicines debate
-
18 May 2016 Cameron Lockwood
A new and easy way to access our multi client studies
-
21 April 2016 Angelica Kershaw
The latest on the spread of Zika and developments to address the current outbreak
-
22 March 2016 Tania Rodrigues
A close look at the recent developments with DRGs
-
06 March 2016 Cameron Lockwood
In late February, the Obama administration announced a number of actions designed to accelerate the development of precision medicine in the...
-
29 February 2016 Eoin Ryan
The new EFPIA code introduces a significant new level of public scrutiny
-
02 February 2016 Choukri Genane
A close look at the proposed appointment of haematology specialist Buzyn Agnes
-
10 January 2016 Cecilia Chui
A closer look at precision Meds
-
03 January 2016 Zhang, Jing
Understanding Chinese traditional medicine
-
27 December 2015 Zhang, Jing
Understanding the twentieth-largest pharmaceutical market in the world
-
21 December 2015 Brendan Melck
How over the counter meds are changing the market landscape
-
10 December 2015 Milena Izmirlieva
A look at the pricing for PCSK9 inhibitors for cholesterol
-
07 December 2015 Floriane Reinaud
Options when the price requested by the pharmaceutical company is believed to be too high
-
02 December 2015 Sophie Cairns
Vietnam's pharmaceutical sector is expected to see the fiercest competition
-
30 November 2015 Maria McGee
Time and again when we explore ways in which we can streamline market access, secure reimbursement and even refine pharmaceutical pricing, we...
-
23 November 2015 Gustav Ando
Insights on the Pfizer/ Allergan merger
-
19 November 2015 Brendan Melck
What are the implications for healthcare following the elections?
-
17 November 2015 Milena Izmirlieva
Insights from ISPOR Milan - parallel scientific advice by regulatory agencies and HTA agencies
-
15 November 2015 Gustav Ando
A healthcare system in crisis, a pharmaceutical industry in decline, and acute shortages of essential medicines
-
13 November 2015 Milena Izmirlieva
Insights from ISPOR Milan 2015 on managed entry agreements
-
10 November 2015 Tania Rodrigues
Discounts usually offered to distributors and retailers will be slashed
-
09 November 2015 Gustav Ando
Insights from ISPOR Milan
-
08 November 2015 Kavita Rainova
Is England's Cancer Drug Fund sustainable?
-
04 November 2015 Cameron Lockwood
The value of molecular testing will increasingly hinge on experimental demonstration of clinical utility
-
03 November 2015 Eoin Ryan
Ongoing price reductions negotiations covering the supply of innovative medicines
-
30 October 2015 Gustav Ando
Booth 1015 and during session 3 of research posters
-
26 October 2015 Angelica Kershaw
Insights from ISPOR Latin America on HTA and centralized procurement
-
20 October 2015 Sophie Cairns
In Hong Kong's flourishing black market, costly branded drugs can be bought at a fraction of their market price
-
13 October 2015 Maria McGee
A close look at AstraZeneca´s most recent biomarker technology collaboration
-
09 October 2015 Choukri Genane
A look at the ongoing struggle for the French government with its health deficit
-
05 October 2015 Tania Rodrigues
The state of precision medicine in Spain
-
14 September 2015 Kavita Rainova
The vaccines situation raises concerns over the potential rise in other vaccine-preventable diseases
-
09 September 2015 Mark Hollis
Governments in the region are increasingly working together to harmonize regulatory approvals
-
03 September 2015 Floriane Reinaud
Can European governments fund new and innovative pharmaceuticals given their growing debt?
-
27 August 2015 Eoin Ryan
Diabetes-related social and economic costs amounted to DKK31.8 billion (USD4.75 billion) in 2011, corresponding to DKK107,000 (USD16,000) per...
-
25 August 2015 Cameron Lockwood
A close look at the market-specific differences in terms of how payers would like to see manufacturers address the REA gap
-
19 August 2015 Sophie Cairns
IHS Life Sciences expects the explosion to cause significant disruption to the shipment of non-time-sensitive pharmaceutical exports
-
17 August 2015 Cecilia Chui
What gets covered when a patient receives both insured and uninsured treatments in the same medical care series?
-
31 July 2015 Cameron Lockwood
Understanding what's at stake, and behind, the changes within the Saudi MOH
-
28 July 2015 Tania Rodrigues
The quest to dramatically change the molecular diagnostic landscape and ultimately provide a global vision of cancer treatment in Spain.
-
23 July 2015 Angelica Kershaw
According to the MoH, with the implementation of these partnerships the Brazilian government has achieved BRL2.5 billion (USD782.2 million) in...
-
21 July 2015 Mark Hollis
Does the UNAIDS report whitewash over the very real funding crisis facing HIV treatment programs?
-
16 July 2015 Kavita Rainova
Do these new documents point to a single drugs market within the Eurasian Economic Union (EEU)?
-
14 July 2015 Wayne Su
Using our disease prevention microsimulation model to understand the true burden of disease
-
08 July 2015 Sophie Cairns
Thailand's battle against runaway pharmaceutical prices.
-
06 July 2015 Zhang, Jing
A closer look at South Korea's healthcare economy
-
30 June 2015 Milena Izmirlieva
Are there signs of actual changes in the United States P&R environment as a result of the 'Sovaldi Effect'?
-
26 June 2015 Margaret Labban
A global perspective on Gilead's pricing strategy. The Sovaldi debate continues
-
22 June 2015 Kavita Rainova
A closer look at the Ukrainian healthcare system amidst the country's ongoing turmoil
-
17 June 2015 Maria McGee
Sweden looks to reform its pricing model.
-
14 June 2015 Tania Rodrigues
Is global action needed to curb wide-spread use of antibiotics and the development of drug-resistant bacteria?
-
05 June 2015 Cecilia Chui
Tracking shifts in MENA healthcare systems
-
02 June 2015 Cameron Lockwood
The Middle East and North Africa is a region once again on the radar, following recent rumours that Valeant is considering a bid for Egypt's...
-
27 May 2015 Angelica Kershaw
A close look at the drug shortages in Venezuela
-
19 May 2015 Gustav Ando
Insights on regulations from #ISPORPhila
-
18 May 2015 Gustav Ando
insights from #ISPORPhila 2015
-
14 May 2015 Brendan Melck
Insights from the European Generics Association's (EGA) annual biosimilars conference.
-
12 May 2015 Margaret Labban
On average, an estimated CAD7.3 billion (USD5.95 billion) in savings could be achieved in Canada through a universal drug plan.
-
07 May 2015 Gustav Ando
IHS Life Sciences will be at ISPOR May 16-20
-
05 May 2015 Mark Hollis
A look at the changing healthcare policy in India. Is it the end of the move towards universal coverage?
-
29 April 2015 Cameron Lockwood
A look at the "barriers to access" for Sovaldi
-
26 April 2015 Floriane Reinaud
IHS Life Sciences analysed price changes for innovative drugs approved by the European Medicines Agency (EMA) that were priced in 2009 and afterwards....
-
24 April 2015 Mark Hollis
In the lead-up to World Malaria Day, the World Health Organization has published new guidelines on the clinical management of malaria. In addition...
-
23 April 2015 Sophie Cairns
A look at China's CFDA new regulations on far-flung corners of its pharmaceutical sector: multi-regional clinical trials, biosimilars, drug evaluation...
-
21 April 2015 April Semilla
The importance of Health Impact Assessments (HIA) as a means of adding unique insights to a one dimensional analysis
-
15 April 2015 Praful Mehta
A look at M&A activity for the industry
-
13 April 2015 Angelica Kershaw
A deeper look at Colombia's "healthcare statutory law
-
09 April 2015 Brendan Melck
Poland's pharmaceutical industry has reacted with strong condemnation to a letter sent by the deputy health minister to the country's health...
-
06 April 2015 Federica Benassi
Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab) are expected to become the next cardiovascular blockbusters able to...
-
02 April 2015 Maria McGee
The Swedish government has announced it is drawing on Danish experiences to improve cancer care by introducing standardised cancer care pathways...
-
31 March 2015 Margaret Labban
The pricing and reimbursement (P&R) landscape for pharmaceuticals is gradually changing in Canada, particularly as the provinces have banded...
-
25 March 2015 Anne-Charlotte Ackermann
We examine how the new pharmaco-economic evaluations impact market access conditions for innovative medicines in France.
-
23 March 2015 Zhang, Jing
A close look at the the outlook for the Philippines and the pros and cons of joining the Trans-Pacific Partnership (TPP)